Trial Profile
Nivolumab monotherapy in Rare tumor patients with mismatch repair deficiency biomarker: A phase II trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 30 Apr 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Cancer
- Focus Therapeutic Use
- Acronyms ROCK trial
- 16 Apr 2021 Status changed from recruiting to active, no longer recruiting.
- 24 Apr 2018 New trial record